The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis

References

• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035–8
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams K, Strausser BP. ADHERE (acute decompensated heart failure national registry): rationale, design, and subject population. J Card Fail 2002;8:S49
   Google Scholar
• Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433–41
   PubMed Web of Science ®Google Scholar
• Bobbio M, Ferrua S, Opasich C, et al. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003;9:192–202
   PubMed Web of Science ®Google Scholar
• Fonarow GC. The management of the diabetic patient with prior cardiovascular events. Rev Cardiovasc Med 2003;(Suppl 6):S38–49
   Google Scholar
• Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997;3:173–9
   PubMedGoogle Scholar
• CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13
   PubMed Web of Science ®Google Scholar
• Howard BV, Rodriguez BL, Bennett PH, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002;105:e132–7
   PubMed Web of Science ®Google Scholar
• Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374–81
   Google Scholar
• Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100: 1134–46
   PubMed Web of Science ®Google Scholar
• Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017–20
   PubMed Web of Science ®Google Scholar
• Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708–14
   Google Scholar
• Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38:421–8
   PubMed Web of Science ®Google Scholar
• MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–8
   PubMed Web of Science ®Google Scholar
• Gupta R, Tang WH, Young JB. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 2004;147:79–83
   Google Scholar
• Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004;116(Suppl 5A):76S–88
   Google Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905–12
   PubMed Web of Science ®Google Scholar
• Bell DS. Beta adrenergic blocking agents in patients with diabetes – friend and foe. Endocr Pract 1999;5:51–3
   PubMedGoogle Scholar
• Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens 1994;8:257–63
   PubMed Web of Science ®Google Scholar
• Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–73
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta- blocking agents? Am J Hypertens 1998;11:1258–65
   Google Scholar
• Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282–9
   PubMed Web of Science ®Google Scholar
• Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146:848–53
   PubMed Web of Science ®Google Scholar
• Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–38
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159–67
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817–25
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14: 489–94
   PubMed Web of Science ®Google Scholar
• Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263: 92–8
   PubMed Web of Science ®Google Scholar
• Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455–61
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non- insulin- dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955–9
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227–36
   PubMed Web of Science ®Google Scholar
• Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349: 375–80
   Google Scholar
• Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807–16
   PubMed Web of Science ®Google Scholar
• CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–90
   PubMed Web of Science ®Google Scholar
• Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800–6
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793–9
   Google Scholar
• Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000;21:1259–64
   PubMed Web of Science ®Google Scholar
• Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients – beneficial effects of carvedilol: a double- blind, placebo-controlled trial. J Am Coll Cardiol 2001;37: 407–11
   PubMed Web of Science ®Google Scholar
• Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004;147:324–30
   PubMed Web of Science ®Google Scholar
• Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469–79
   PubMed Web of Science ®Google Scholar
• Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Presented at the American Heart Association 74th Annual scientific Session; 14 November 2001, Anaheim, CA. Circulation 2001;104(Suppl II):II-754 [abstract 3551]
   Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309–21
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13
   Google Scholar
• Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(Suppl B):8–16
   Google Scholar
• Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790–804
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart disease and stroke statistics – 2005 update. Dallas, TX: American Heart Association, 2005
   Google Scholar
• Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002;25: 1722–8
   Google Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452–4
   PubMed Web of Science ®Google Scholar